CGBIO

CGBIO

CGBIO manages the private investment portfolio for the family behind CG Bio, a publicly traded Korean manufacturer of spinal implants and regenerative medicine products. The firm's investment posture is anchored in the family's deep operating experience in orthopedics and biologics. CG Bio, founded in 2006 and listed on KOSDAQ, generates the underlying wealth through its core business supplying implantable devices to hospitals across Asia. The office pursues direct investments and selected fund commitments across medical devices, digital health, and life sciences platforms. CGBIO typically targets growth-stage and late-stage companies where the family's clinical and regulatory expertise can add value beyond capital. Geographic focus spans South Korea, the United States, and select opportunities in Southeast Asia. The firm evaluates deals related to surgical robotics, biomaterials, and orthopedic innovations — areas adjacent to the operating company's core competencies. Team size and total deployment remain undisclosed. CGBIO operates from Seoul without known additional offices. The family maintains a low public profile, with investment activities conducted through the private office rather than through the listed entity. No recent fund closes or major transactions have been publicly attributed to the office. Structurally, CGBIO exemplifies the Korean operating-company family office model, where the investment vehicle is an extension of the founder's industrial expertise rather than a diversified asset manager. The office's edge lies in its technical due-diligence capability within orthopedic technologies — a domain where the founding family holds deep, non-obvious knowledge from decades of manufacturing and clinical collaboration.